Compare COOK & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | ENTX |
|---|---|---|
| Founded | 1985 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.7M | 74.7M |
| IPO Year | 2021 | 2015 |
| Metric | COOK | ENTX |
|---|---|---|
| Price | $28.17 | $1.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $58.00 | $10.00 |
| AVG Volume (30 Days) | ★ 535.0K | 104.7K |
| Earning Date | 03-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | ★ $559,520,000.00 | $181,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.50 | N/A |
| P/E Ratio | ★ N/A | $6.56 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $1.00 |
| 52 Week High | $35.56 | $3.22 |
| Indicator | COOK | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 79.73 | 36.77 |
| Support Level | $0.98 | $1.00 |
| Resistance Level | N/A | $1.61 |
| Average True Range (ATR) | 1.45 | 0.16 |
| MACD | 3.40 | -0.01 |
| Stochastic Oscillator | 77.71 | 6.12 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.